More Articles

Data exclusivity is not the same as market exclusivity Policies & Legislation | Posted 26/01/2010

Gene Quinn distinguishes facts from fiction on biosimilars on IPWatchdog.com.According to him, data exclusivity is not the same as market exclusivity. “During a period of data exclusivity, a compet...

Minimal 12 years of biologicals data exclusivity required Biosimilars/News | Posted 26/01/2010

As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States.

Innovative biologicals development must be preserved Pharma News | Posted 26/01/2010

As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States, and in the first weekend of December...

Will Teva join Big Pharma by 2015? Generics/News | Posted 25/01/2010

Teva Pharmaceutical Industries’ annual revenue will probably more than double to US$31 billion by 2015, as rising healthcare costs push patients and policy makers toward (bio)generic drugs, Chief E...

Steady gains in perceptions of generics in Japan Generics/News | Posted 25/01/2010

As reported by Scrip News on 17 December 2009, the latest survey of patient and pharmacist perceptions of generic drugs in Japan shows a high percentage of patients would be willing to receive such...

Teva seeks closer ties with Lonza on biosimilars Biosimilars/News | Posted 25/01/2010

Biogenerics is a field that is becoming more and more important to Teva and the company seeks to deepen its existing ties in this area with Swiss company Lonza. Sources inform Globes that Teva Pres...

Pfizer’s biosimilars strategy Biosimilars/News | Posted 22/01/2010

“I think it is a good strategy for a large company like Pfizer that wants to be a player in generics”, Ronny Gal, a Sanford C Bernstein Analyst in New York said. “I would be surprised if they weren...

Pfizer and the US Biosimilars Pathway Policies & Legislation | Posted 22/01/2010

Both the US House and Senate healthcare bills include language that would allow US regulators to set up a method for approving copies of biotechnology drugs. Under the proposals, biologicals would...